Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening

Health Technology Assessment

Volumn 19, Issue 74, 2015, Pages 1-116

  Scanlon, Peter H ^a   Aldington, Stephen J ^a   Leal, Jose ^b   Luengo Fernandez, Ramon ^b   Oke, Jason ^b   Sivaprasad, Sobha ^c   Gazis, Anastasios ^d   Stratton, Irene M ^a  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DISEASE COURSE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HIDDEN MARKOV MODEL; HUMAN; INDIVIDUALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED KINGDOM; VISION TEST; VISUAL SYSTEM EXAMINATION; AGED; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; MASS SCREENING; MIDDLE AGED; OUTCOME ASSESSMENT; THEORETICAL MODEL; TIME FACTOR;

AGED; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TIME FACTORS; UNITED KINGDOM;

EID: 84942092793     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19740     Document Type: Article

References (108)

1. Roberts S. Turning the Corner: Improving Diabetes Care. London: Department of Health; 2006.
2. International Diabetes Federation. Diabetes Atlas. International Diabetes Federation; 2006. URL: www.idf.org/sites/default/files/Diabetes-Atlas-3rd-edition.pdf (accessed 7 July 2015).
3. The Lancet. Type 2 diabetes epidemic: a global education. Lancet 2009;374:1654. http://dx.doi.org/10.1016/S0140-6736(09)61974-7
4. Department of Health. Vital Signs Monitoring 2011. London: Department of Health; 2011.
5. Department of Health. Integrated Performance Measures Monitoring 2011. URL: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/Performancedataandstatistics/Integratedperfomancemeasuresmonitoring/DH_112536 (accessed 5 March 2012).
6. Diabetes UK. Number of People Diagnosed with Diabetes Reaches Three Million. URL: www.diabetes.org.uk/About_us/News_Landing_Page/Number-of-people-diagnosed-withdiabetes-reaches-three-million/ (accessed 25 April 2014).
7. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002;86:716–22. http://dx.doi.org/10.1136/bjo.86.7.716
8. Congdon N, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003;290:2057–60. http://dx.doi.org/10.1001/jama.290.15.2057
9. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 2000;78:374–85. http://dx.doi.org/10.1034/j.1600-0420.2000.078004374.x
10. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 2014;4:e004015. http://dx.doi.org/10.1136/bmjopen-2013-004015
11. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabet Care 2009;32:2307–13. http://dx.doi.org/10.2337/dc09-0615
12. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859–68. http://dx.doi.org/10.1016/j.ophtha.2008.08.023
13. DRS. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number
14. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88:583–600.
15. ETDRS. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number
16. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796–806. http://dx.doi.org/10.1001/archopht.1985.01050120030015
17. Tu KL, Palimar P, Sen S, Mathew P, Khaleeli A. Comparison of optometry vs digital photography screening for diabetic retinopathy in a single district. Eye 2004;18:3–8. http://dx.doi.org/10.1038/sj.eye.6700497
18. Savolainen EA, Lee QP. Diabetic retinopathy - need and demand for photocoagulation and its cost-effectiveness: evaluation based on services in the United Kingdom. Diabetologia 1982;23:138–40. http://dx.doi.org/10.1007/BF01271176
19. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164–9. http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00017
20. Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabet Care 2002;25:476–81. http://dx.doi.org/10.2337/diacare.25.3.476
21. Fendrick AM, Javitt JC, Chiang YP. Cost-effectiveness of the screening and treatment of diabetic retinopathy. What are the costs of underutilization? Int J Technol Assess Health Care 1992;8:694–707. http://dx.doi.org/10.1017/S0266462300002385
22. Nystrom L, Dahlquist G, Ostman J, Wall S, Arnqvist H, Blohme G, et al. Risk of developing insulin-dependent diabetes mellitus (IDDM) before 35 years of age: indications of climatological determinants for age at onset. Int J Epidemiol 1992;21:352–8. http://dx.doi.org/10.1093/ije/21.2.352
23. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes. A National Clinical Guideline. Edinburgh: Royal College of Physicians; 2010. URL: www.sign.ac.uk/pdf/sign116.pdf (accessed 28 October 2014).
24. Misra A, Bachmann MO, Greenwood RH, Jenkins C, Shaw A, Barakat O, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med 2009;26:1040–7. http://dx.doi.org/10.1111/j.1464-5491.2009.02820.x
25. Kristinsson JK, Gudmundsson JR, Stefansson E, Jonasson F, Gislason I, Thorsson AV. Screening for diabetic retinopathy. Initiation and frequency. Acta Ophthalmol Scand 1995;73:525–8. http://dx.doi.org/10.1111/j.1600-0420.1995.tb00329.x
26. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med 2003;20:758–65. http://dx.doi.org/10.1046/j.1464-5491.2003.01035.x
27. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361:195–200. http://dx.doi.org/10.1016/S0140-6736(03)12267-2
28. Olafsdottir E, Stefansson E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol 2007;91:1599–601. http://dx.doi.org/10.1136/bjo.2007.123810
29. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889–96. http://dx.doi.org/10.1001/jama.283.7.889
30. Mehlsen J, Erlandsen M, Poulsen PL, Bek T. Individualized optimization of the screening interval for diabetic retinopathy: a new model. Acta Ophthalmol 2012;90:109–14. http://dx.doi.org/10.1111/j.1755-3768.2010.01882.x
31. Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabet Care 2004;27:2540–53. http://dx.doi.org/10.2337/diacare.27.10.2540
32. Raymond NT, Varadhan L, Reynold DR, Bush K, Sankaranarayanan S, Bellary S, et al. Higher prevalence of retinopathy in diabetic patients of south Asian ethnicity compared to white Europeans in the community: a cross sectional study. Diabet Care 2009;32:410–15. http://dx.doi.org/10.2337/dc08-1422
33. Sivaprasad S, Gupta B, Gulliford MC, Dodhia H, Mann S, Nagi D, et al. Ethnic variation in the prevalence of visual impairment in people attending diabetic retinopathy screening in the United Kingdom (DRIVE UK). PLOS ONE 2012;7:e39608. http://dx.doi.org/10.1371/journal.pone.0039608
34. Sivaprasad S, Gupta B, Gulliford MC, Dodhia H, Mohamed M, Nagi D, et al. Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (DRIVE UK). PLOS ONE 2012;7:e32182. http://dx.doi.org/10.1371/journal.pone.0032182
35. Stratton IM, Provins E, Histed M, Chave S, Scanlon PH. Relationship of diabetic retinopathy levels with duration of diabetes and HbA1c in an English screening programme (poster 515 DUK Annual Conference). Diabet Med 2011;28:187.
36. Milton RC, Ganley JP, Lynk RH. Variability in grading diabetic retinopathy from stereo fundus photographs: comparison of physician and lay readers. Br J Ophthalmol 1977;61:192–201. http://dx.doi.org/10.1136/bjo.61.3.192
37. Glasziou P, Irwig L, Deeks JJ. When should a new test become the current reference standard? Ann Intern Med 2008;149:816–22. http://dx.doi.org/10.7326/0003-4819-149-11-200812020-00009
38. Keenan K, Hayen A, Neal BC, Irwig L. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ 2009;338:1260. http://dx.doi.org/10.1136/bmj.b1492
39. Oke JL, Stevens RJ, Gaitskell K, Farmer AJ. Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model. Diabet Med 2012;29:266–71. http://dx.doi.org/10.1111/j.1464-5491.2011.03412.x
40. Farmer AJ, Stevens R, Hirst J, Lung T, Oke J, Clarke P, et al. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment – systematic review and modelling of progression and cost-effectiveness. Health Technol Assess 2014;18(14). http://dx.doi.org/10.3310/hta18140
41. Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabet Care 2013;36:580–5. http://dx.doi.org/10.2337/dc12-0625
42. Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124:1754–60. http://dx.doi.org/10.1001/archopht.124.12.1754
43. Happich M, Reitberger U, Breitscheidel L, Ulbig M, Watkins J. The economic burden of diabetic retinopathy in Germany in 2002. Graefes Arch Clin Exp Ophthalmol 2008;246:151–9. http://dx.doi.org/10.1007/s00417-007-0573-x
44. Baker M, Thornton P, Vernon A, Winyard A. The Costs of Blindness. Royal National Institute of Blind People Campaign Report. London: Royal National Institute for the Blind; 2000. pp. 1–69.
45. Royal National Institute of Blind People and Diabetes UK. Don’t Turn a Blind Eye. 2006. URL: www.diabetes.org.uk/Documents/Reports/Dont_turn_a_blind_eye_0606.pdf
46. Department of Health. National Service Framework for Diabetes: Delivery Strategy. London: Department of Health; 2003.
47. National Information Governance Board for Health and Social Care. URL: http://webarchive.nationalarchives.gov.uk/20130513181011/http://www.nigb.nhs.uk/ (accessed 7 July 2015).
48. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010;27:249–56. http://dx.doi.org/10.1111/j.1464-5491.2009.02870.x
49. Brailsford SC, Rauner MS, Gutjahr WJ, Zeppelzauer W. Combined discrete-event simulation and ant colony optimisation approach for selecting optimal screening policies for diabetic retinopathy. Comput Manage Sci 2007;4:59–83. http://dx.doi.org/10.1007/s10287-006-0008-x
50. Davies R, Roderick P, Canning C, Brailsford S. The evaluation of screening policies for diabetic retinopathy using simulation. Diabet Med 2002;19:762–70. http://dx.doi.org/10.1046/j.1464-5491.2002.00773.x
51. National Institute for Health and Care Excellence (NICE). Updated guide to the methods of technology appraisal. London: NICE; 2008.
52. ENSPDR. Excluding Patients from the NHS Diabetic Retinopathy Screening Programme Temporarily or Permanently 2006.
53. NICE. Open Athens account 2014. URL: www.evidence.nhs.uk/about-evidence-services/journals-and-databases (accessed 12 April 2014).
54. Scanlon PH, Provins EK, Craske S, Chave SJ, Aldington SJ, Martin CN, et al. Updating diabetic retinopathy screening lists using automatic extraction from GP patient records. J Med Screen 2013;20:111–17. http://dx.doi.org/10.1177/0969141313505747
55. Scanlon PH, Stratton IM, Histed M, Chave SJ, Aldington SJ. The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. Acta Ophthalmol 2013;91:e335–9. http://dx.doi.org/10.1111/aos.12074
56. Taylor-Phillips S, Mistry H, Leslie R, Todkill D, Tsertsvadze A, Connock M, et al. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review [published online ahead of print 13 January 2015]. Br J Ophthalmol 2015. http://dx.doi.org/10.1136/bjophthalmol-2014-305938
57. Scanlon PH, Loftus J, Starita C, Stratton IM. The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. Diabet Med 2015;32:97–101. http://dx.doi.org/10.1111/dme.12593
58. Healy R, Sallam A, Jones V, Donachie PH, Scanlon PH, Stratton IM, et al. Agreement between photographic screening and hospital biomicroscopy grading of diabetic retinopathy and maculopathy. Eur J Ophthalmol 2014;24:550–8. http://dx.doi.org/10.5301/ejo.5000404
59. Sallam A, Scanlon PH, Stratton IM, Jones V, Martin CN, Brelen M, et al. Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathy. Diabet Med 2011;28:741–6. http://dx.doi.org/10.1111/j.1464-5491.2011.03273.x
60. Arun CS, Ngugi N, Lovelock L, Taylor R. Effectiveness of screening in preventing blindness due to diabetic retinopathy. Diabet Med 2003;20:186–90. http://dx.doi.org/10.1046/j.1464-5491.2003.t01-1-00899.x
61. Aspelund T, Thornorisdottir O, Olafsdottir E, Gudmundsdottir A, Einarsdottir AB, Mehlsen J, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 2011;54:2525–32. http://dx.doi.org/10.1007/s00125-011-2257-7
62. SAS. Analyzing Receiver Operating Characteristic Curves Using SAS 2007. URL: www.sas.com/storefront/aux/en/spanlyrecop/60610_excerpt.pdf (accessed 29 October 2014).
63. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–72; discussion 207–12. http://dx.doi.org/10.1002/sim.2929
64. Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol 2014;14:40. http://dx.doi.org/10.1186/1471-2288-14-40
65. Marshall G, Jones RH. Multi-state models and diabetic retinopathy. Stat Med 1995;14:1975–83. http://dx.doi.org/10.1002/sim.4780141804
66. Chen AHH, Duffy SW, Tabar L. A Markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. Statistician 1996;3:307–17. http://dx.doi.org/10.2307/2988469
67. NICE. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update): National Collaborating Centre for Chronic Conditions (UK). Royal College of Physicians; 2008. URL: www.nice.org.uk/guidance/cg66/resources/cg66-type-2-diabetes-full-guideline2 (accessed 28 October 2014).
68. American Diabetes Association. American Diabetes Association: Standards of Medical Care in Diabetes – 2013. Diabet Care 2013;36:S11–66. http://dx.doi.org/10.2337/dc13-S011
69. Australian Government: National Health and Medical Research Council. Guidelines for the Management of Diabetic Retinopathy 2008. URL: www.nhmrc.gov.au/publications (accessed 28 October 2014).
70. Canadian Diabetes Association. Canadian Diabetes Association Clinical Practice Guideline Expert Committee. Can J Diabetes 2013;37:S1. http://dx.doi.org/10.1016/j.jcjd.2013.01.038
71. International Diabetes Federation. The Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence 2011. URL: www.idf.org/global-idfispad-guideline-diabetes-childhood-andadolescence (accessed 28 October 2014).
72. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–63. http://dx.doi.org/10.1007/s001250051594
73. Jackson C. Multi-state modelling with R: the msm package 2007. URL: http://leg.ufpr.br/lib/exe/fetch.php/projetos:msc:msm-manual.pdf (accessed 28 October 2014).
74. R CoreTeam. R: A Language and Environment for Statistical Computing 2012. URL: www.r-project.org/ (accessed 28 October 2014).
75. Shuster S. Malignant melanoma: how error amplification by screening creates spurious disease. Br J Dermatol 2009;161:977–9. http://dx.doi.org/10.1111/j.1365-2133.2009.09399.x
76. Diggle PJ. Estimating prevalence using an imperfect test. Epidemiol Res Int 2011:1–5. http://dx.doi.org/10.1155/2011/608719
77. Liu WJ, Lee LT, Yen MF, Tung TH, Williams R, Duffy SW, et al. Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: implication for diabetic retinopathy screening in Taiwan. Diabet Med 2003;20:727–33. http://dx.doi.org/10.1046/j.1464-5491.2003.01019.x
78. Kalm H, Egertsen R, Blohme G. Non-stereo fundus photography as a screening procedure for diabetic retinopathy among patients with type II diabetes. Compared with 60D enhanced slit-lamp examination. Acta Ophthalmol (Copenh) 1989;67:546–53. http://dx.doi.org/10.1111/j.1755-3768.1989.tb04106.x
79. Olson JA, Strachan FM, Hipwell JH, Goatman KA, McHardy KC, Forrester JV, et al. A comparative evaluation of digital imaging, retinal photography and optometrist examination in screening for diabetic retinopathy. Diabet Med 2003;20:528–34. http://dx.doi.org/10.1046/j.1464-5491.2003.00969.x
80. Scanlon PH, Malhotra R, Greenwood RH, Aldington SJ, Foy C, Flatman M, et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. Br J Ophthalmol 2003;87:1258–63. http://dx.doi.org/10.1136/bjo.87.10.1258
81. Scanlon PH, Malhotra R, Thomas G, Foy C, Kirkpatrick JN, Lewis-Barned N, et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabet Med 2003;20:467–74. http://dx.doi.org/10.1046/j.1464-5491.2003.00954.x
82. Stellingwerf C, Hardus PL, Hooymans JM. Two-field photography can identify patients with vision-threatening diabetic retinopathy: a screening approach in the primary care setting. Diabetes Care 2001;24:2086–90. http://dx.doi.org/10.2337/diacare.24.12.2086
83. van der Heijden AA, Walraven I, van’t Riet E, Aspelund T, Lund SH, Elders P, et al. Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy. Diabetologia 2014;57:1332–8. http://dx.doi.org/10.1007/s00125-014-3246-4
84. Sachdeva A, Stratton IM, Unwin J, Moreton R, Scanlon PH. Diabetic retinopathy screening: study to determine risk factors for non-attendance. Diabet Prim Care 2012;14:308–16.
85. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BE. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991;29:20–39. http://dx.doi.org/10.1097/00005650-199101000-00003
86. Bachmann M, Nelson SJ. Screening for Diabetic Retinopathy: A Quantitative Overview of the Evidence, Applied to the Populations of Health Authorities and Boards. Report. Bristol: Health Care Evaluation Unit, University of Bristol; 1996.
87. James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000;320:1627–31. http://dx.doi.org/10.1136/bmj.320.7250.1627
88. Gillow JT, Gray JA. The National Screening Committee review of diabetic retinopathy screening. Eye 2001;15:1–2. http://dx.doi.org/10.1038/eye.2001.1
89. NICE. Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children and Young People. London: NICE; 2004.
90. Brailsford SC, Gutjahr WJ, Rauner MS, Zeppelzauer W. Combined discrete-event simulation and ant colony optimisation approach for selecting optimal screening policies for diabetic retinopathy. Computat Manag Sci 2007;4:59–83. http://dx.doi.org/10.1007/s10287-006-0008-x
91. Royal National Institute of Blind People. Future Sight Loss UK: The Economic Impact of Partial Sight and Blindness in the UK Adult Population 2009. URL: www.rnib.org.uk/sites/default/files/FSUK_Report.pdf (accessed 29 October 2014).
92. Rein DB, Wittenborn JS, Zhang X, Allaire BA, Song MS, Klein R, et al. The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy. Health Serv Res. 2011;46:1534–61. http://dx.doi.org/10.1111/j.1475-6773.2011.01263.x
93. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2012;12:CD007419. http://dx.doi.org/10.1002/14651858.cd007419.pub3
94. Curtis L. Unit Costs of Health and Social Care 2013. Canterbury: Personal Social Services Research Unit, University of Kent; 2013. URL: www.pssru.ac.uk/project-pages/unit-costs/2013/index.php?file=full˝ Similar (accessed 29 October 2014).
95. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 2010;87:15–19. http://dx.doi.org/10.1016/j.diabres.2009.10.006
96. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS Diabetologia. 2013;56:1925–33. http://dx.doi.org/10.1007/s00125-013-2940-y
97. Poku E, Brazier J, Carlton J, Ferreira A. Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review. BMC Ophthalmol 2013;13:74. http://dx.doi.org/10.1186/1471-2415-13-74
98. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618–24. http://dx.doi.org/10.1111/j.1464-5491.2008.02430.x
99. Department of Health. NHS Reference Costs 2009–2010. 2011. URL: www.gov.uk/government/publications/nhs-reference-costs-2009-2010 (accessed 29 October 2014).
100. Department of Health. National Tariff Payment System 2014/15. 2013. URL: www.gov.uk/government/publications/national-tariff-payment-system-2014-to-2015 (accessed 29 October 2014).
101. Department of Health. NHS Reference Costs 2012 to 2013. 2013. URL: www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 (accessed 29 October 2014).
102. Evans JR, Smeeth L, Fletcher AE. Risk of admission to a nursing home among older people with visual impairment in Great Britain. Arch Ophthalmol 2008;126:1428–33. http://dx.doi.org/10.1001/archopht.126.10.1428
103. Age UK. Later Life in the United Kingdom. 2015. URL: www.ageuk.org.uk/Documents/EN-GB/Factsheets/Later_Life_UK_factsheet.pdf?dtrk=true (accessed 20 March 2015).
104. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
105. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779–87. http://dx.doi.org/10.1002/hec.635
106. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health 2012;15:812–20. http://dx.doi.org/10.1016/j.jval.2012.06.014
107. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676–82. http://dx.doi.org/10.1093/aje/kwq433
108. Scanlon PH, Aldington SJ, Stratton IM. Delay in diabetic retinopathy screening increases the rate of detection of referable diabetic retinopathy. Diabet Med 2014;31:439–42. http://dx.doi.org/10.1111/dme.12313